Taprizosin Mesylate

N/A

Report date: 2022/01/14 13:23:58

NME

Base Information

Drug NameTaprizosin Mesylate

Drug Alias Name他普利唑嗪taprizosinetaprizosina他立唑嗪taprizosinum +[6]

ClassificationSmall molecules > Heterocyclic drugs

Mechanisms of ActionAlpha-1a adrenergic receptor antagonists

TargetsAlpha-1a adrenergic receptor

Therapy Area/IndicationsProstatic Hyperplasia

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusDiscontinued (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesPfizer Inc

China Registration ClassN/A

Active CompaniesN/A

Inactive CompaniesPfizer Inc

Active IndicationsN/A

Inactive IndicationsProstatic Hyperplasia

ATC CodeN/A